Q3 FY 02/23
results supplementary material
These materials contain our earnings outlook. While our earnings outlook and views are based on internal and other reliable data, they do not constitute a guarantee of our future earnings. Therefore, sales and profits may differ from the figures outlined in this material.
The figures in these materials are rounded down to the nearest million yen.
Jan.12th, 2023
Hisamitsu Pharmaceutical Co., Inc.
(Security code number: 4530)
Consolidated Financial Statement
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | As a % | |
(Unit: ¥mn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | of total |
Current assets | 180,018 | 191,553 | 193,241 | 191,418 | 192,461 | 200,319 | 205,531 | 209,251 | 195,780 | 197,445 | 196,460 | 198,061 | 198,804 | 206,060 | 203,988 | 200,176 | 197,860 | 215,141 | 219,150 | 65.1% |
Cash & deposits | 110,016 | 116,896 | 104,241 | 110,283 | 115,710 | 108,901 | 104,555 | 107,051 | 101,158 | 117,039 | 111,991 | 114,254 | 120,361 | 125,682 | 119,908 | 129,290 | 128,294 | 136,460 | 133,994 | |
Notes and accounts receivable - trade, and contract assets | 35,122 | 35,940 | 35,060 | 39,961 | 33,701 | 41,535 | 39,587 | 49,232 | 37,898 | 31,955 | 32,128 | 39,546 | 31,969 | 34,102 | 33,083 | 38,505 | 33,019 | 37,800 | 37,775 | |
Marketable securities | 13,981 | 15,828 | 21,390 | 20,946 | 21,045 | 21,879 | 34,893 | 34,878 | 33,995 | 22,281 | 22,109 | 21,743 | 22,804 | 22,763 | 23,107 | 13,141 | 13,812 | 14,857 | 15,501 | |
Inventory | 17,323 | 16,924 | 17,742 | 15,760 | 16,816 | 16,185 | 18,204 | 15,460 | 18,203 | 19,513 | 19,986 | 18,569 | 18,307 | 17,548 | 17,435 | 16,412 | 18,267 | 19,547 | 20,306 | |
Other current assets | 3,824 | 6,220 | 15,072 | 4,766 | 5,430 | 12,127 | 8,583 | 2,952 | 4,797 | 6,928 | 10,533 | 4,290 | 5,720 | 6,349 | 10,859 | 3,219 | 4,779 | 6,832 | 11,870 | |
Bad debt provision | -249 | -258 | -267 | -299 | -242 | -311 | -293 | -325 | -273 | -273 | -289 | -343 | -359 | -385 | -405 | -393 | -312 | -356 | -297 | |
Fixed assets | 109,880 | 109,814 | 110,586 | 104,368 | 97,660 | 96,411 | 102,455 | 98,150 | 101,305 | 101,494 | 100,087 | 101,800 | 101,100 | 103,522 | 100,007 | 102,681 | 109,903 | 112,756 | 117,730 | 34.9% |
Tangible fixed assets | 39,134 | 39,666 | 39,790 | 39,556 | 39,100 | 38,936 | 38,695 | 38,596 | 37,973 | 38,147 | 37,151 | 37,354 | 38,460 | 38,368 | 38,480 | 39,069 | 41,184 | 42,263 | 44,453 | |
Buildings and structures | 15,422 | 15,194 | 14,967 | 14,816 | 15,120 | 14,714 | 14,498 | 14,939 | 14,829 | 14,631 | 14,402 | 14,180 | 14,231 | 13,940 | 13,746 | 13,905 | 13,918 | 14,185 | 14,179 | |
Machinery and transport equipment | 7,141 | 7,046 | 6,757 | 6,658 | 6,493 | 6,085 | 6,119 | 6,633 | 6,154 | 6,062 | 5,877 | 6,162 | 6,069 | 6,063 | 5,756 | 6,272 | 6,123 | 6,910 | 7,882 | |
Tools, instruments, etc. | 1,844 | 1,795 | 1,804 | 1,781 | 2,003 | 2,055 | 1,983 | 1,978 | 2,081 | 2,095 | 2,056 | 2,077 | 2,097 | 2,061 | 2,082 | 2,140 | 2,115 | 2,087 | 2,113 | |
Land | 12,497 | 12,535 | 12,571 | 12,348 | 12,353 | 12,324 | 12,320 | 12,340 | 12,317 | 12,301 | 11,912 | 11,897 | 11,920 | 11,927 | 11,933 | 11,956 | 11,981 | 11,931 | 11,994 | |
Construction in progress | 2,155 | 3,027 | 3,599 | 3,860 | 3,017 | 3,652 | 3,640 | 2,520 | 2,407 | 2,887 | 2,734 | 2,822 | 2,891 | 3,196 | 3,813 | 3,646 | 5,892 | 5,955 | 7,072 | |
Lease assets | 73 | 66 | 91 | 91 | 112 | 105 | 133 | 184 | 183 | 169 | 168 | 214 | 1,248 | 1,178 | 1,148 | 1,147 | 1,152 | 1,192 | 1,210 | |
Intangible fixed assets | 3,526 | 3,213 | 2,856 | 1,990 | 1,867 | 1,688 | 1,565 | 1,469 | 1,570 | 1,478 | 1,341 | 1,178 | 1,147 | 1,503 | 1,397 | 1,326 | 1,260 | 1,218 | 1,136 | |
Investments, etc. | 67,220 | 66,934 | 67,939 | 62,820 | 56,692 | 55,786 | 62,194 | 58,083 | 61,761 | 61,868 | 61,593 | 63,267 | 61,493 | 63,651 | 60,128 | 62,286 | 67,459 | 69,274 | 72,141 | |
Investment securities | 58,086 | 57,620 | 58,554 | 53,521 | 47,716 | 46,805 | 53,274 | 48,379 | 52,526 | 52,775 | 53,333 | 54,602 | 53,059 | 54,948 | 51,293 | 52,519 | 57,099 | 58,905 | 61,728 | |
Long-term loans | 30 | 29 | 28 | 27 | 27 | 26 | 21 | 20 | 21 | 20 | 19 | 18 | 17 | 17 | 16 | 16 | 15 | 14 | 14 | |
Deferred tax assets | 720 | 786 | 711 | 814 | 638 | 779 | 838 | 1,287 | 923 | 769 | 860 | 1,047 | 1,041 | 1,233 | 1,225 | 1,153 | 1,709 | 1,713 | 1,660 | |
Other | 8,600 | 8,715 | 8,861 | 8,673 | 8,525 | 8,390 | 8,275 | 8,609 | 8,504 | 8,516 | 7,594 | 7,812 | 7,588 | 7,665 | 7,807 | 8,810 | 8,849 | 8,855 | 8,945 | |
Bad debt provision | -216 | -216 | -216 | -215 | -215 | -215 | -215 | -214 | -214 | -214 | -214 | -214 | -214 | -214 | -214 | -214 | -214 | -214 | -207 | |
Total assets | 289,899 | 301,367 | 303,827 | 295,786 | 290,121 | 296,731 | 307,986 | 307,401 | 297,085 | 298,939 | 296,548 | 299,861 | 299,904 | 309,583 | 303,995 | 302,858 | 307,764 | 327,897 | 336,880 | |
Current liabilities | 31,058 | 34,773 | 35,098 | 30,354 | 31,490 | 36,708 | 40,685 | 41,055 | 31,046 | 30,714 | 30,256 | 30,057 | 26,837 | 31,722 | 34,289 | 32,160 | 42,811 | 48,278 | 51,485 | 15.3% |
Notes and accounts payable | 7,715 | 7,990 | 7,073 | 8,290 | 8,554 | 8,735 | 9,789 | 10,488 | 8,813 | 6,798 | 6,895 | 7,672 | 6,141 | 7,875 | 7,167 | 7,533 | 8,456 | 9,454 | 10,334 | |
Electronically recorded obligations-operating | 5,875 | 6,292 | 6,057 | 5,864 | 6,073 | 8,102 | 8,117 | 8,536 | 7,992 | 6,575 | 5,270 | 7,127 | 4,921 | 5,836 | 5,582 | 5,692 | 6,458 | 7,086 | 6,369 | |
Short-term borrowing | 1,436 | 1,411 | 1,386 | 1,361 | 1,320 | 1,282 | 1,245 | 1,209 | 1,211 | 1,191 | 1,181 | 1,111 | 1,111 | 1,111 | 1,111 | 1,071 | 1,071 | 1,071 | 1,071 | |
Accrued expenses | 4,514 | 5,321 | 4,622 | 5,936 | 4,758 | 5,454 | 4,243 | 7,865 | 3,675 | 4,365 | 4,133 | 6,634 | 4,216 | 4,958 | 4,951 | 6,685 | 5,829 | 4,565 | 5,392 | |
Unpaid expenses | 2,419 | 790 | 2,605 | 1,484 | 2,909 | 1,269 | 2,610 | 1,374 | 2,635 | 1,084 | 2,528 | 1,315 | 2,710 | 1,032 | 2,656 | 1,576 | 2,842 | 1,361 | 2,974 | |
Unpaid tax, etc. | 1,326 | 2,569 | 907 | 868 | 818 | 3,052 | 4,061 | 5,745 | 513 | 1,768 | 532 | 608 | 1,209 | 1,964 | 1,668 | 2,938 | 1,149 | 2,699 | 2,073 | |
Bonus reserves | 490 | 1,415 | 805 | 1,629 | 444 | 1,376 | 742 | 1,558 | 383 | 1,159 | 348 | 1,350 | 339 | 1,229 | 490 | 1,363 | 354 | 1,251 | 530 | |
Reserve for returned goods unsold | 86 | 95 | 98 | 101 | 99 | 125 | 120 | 127 | 93 | 81 | 87 | 103 | 108 | 116 | 118 | 135 | - | - | - | |
Other current liabilities | 7,193 | 8,886 | 11,541 | 4,818 | 6,512 | 7,308 | 9,754 | 4,150 | 5,727 | 7,690 | 9,278 | 4,133 | 6,078 | 7,597 | 10,543 | 5,162 | 16,648 | 20,788 | 22,738 | |
Fixed liabilities | 15,795 | 16,031 | 16,120 | 16,802 | 15,327 | 15,202 | 17,053 | 15,598 | 16,329 | 15,318 | 15,550 | 15,994 | 16,578 | 17,324 | 15,793 | 15,812 | 13,239 | 13,341 | 13,566 | 4.0% |
Long-term borrowing | 488 | 469 | 452 | 433 | 420 | 405 | 388 | 368 | 349 | 326 | 309 | 296 | 273 | 254 | 238 | 219 | 202 | 183 | 166 | |
Provision for pension and remuneration obligations | 7,352 | 7,434 | 7,446 | 7,465 | 7,515 | 7,517 | 7,580 | 7,600 | 7,650 | 7,754 | 7,835 | 7,928 | 7,999 | 8,064 | 8,132 | 8,216 | 8,338 | 8,434 | 8,508 | |
Deferred tax liabilities | 4,177 | 4,318 | 4,466 | 5,223 | 3,511 | 3,013 | 4,545 | 2,978 | 4,350 | 4,460 | 4,709 | 5,126 | 4,818 | 5,524 | 4,275 | 4,171 | 1,790 | 1,790 | 2,024 | |
Other fixed liabilities | 3,777 | 3,809 | 3,754 | 3,680 | 3,880 | 4,266 | 4,538 | 4,652 | 3,977 | 2,777 | 2,695 | 2,643 | 3,486 | 3,480 | 3,147 | 3,205 | 2,908 | 2,933 | 2,867 | |
Total liabilities | 46,853 | 50,805 | 51,218 | 47,157 | 46,817 | 51,911 | 57,738 | 56,654 | 47,376 | 46,033 | 45,806 | 46,051 | 43,415 | 49,046 | 50,082 | 47,972 | 56,051 | 61,620 | 65,051 | 19.3% |
Owners' Equity | 216,497 | 222,201 | 221,896 | 222,657 | 221,159 | 225,515 | 226,728 | 229,945 | 226,711 | 230,565 | 229,181 | 232,707 | 231,662 | 234,317 | 229,674 | 227,495 | 219,910 | 224,798 | 223,527 | 66.4% |
Common stock | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | |
Capital surplus | 5,914 | 5,914 | 5,914 | 5,914 | 5,914 | 5,914 | 2,272 | 2,272 | 2,284 | 2,352 | 2,352 | 2,352 | 2,352 | 2,356 | 2,356 | 2,356 | 2,356 | 2,361 | 2,361 | |
Retained earnings | 236,819 | 242,525 | 243,244 | 249,156 | 247,659 | 253,293 | 227,712 | 230,929 | 227,653 | 231,232 | 229,848 | 233,376 | 232,331 | 234,971 | 232,753 | 236,192 | 228,607 | 233,465 | 233,111 | |
Treasury stock | -34,709-34,712-35,735-40,886 | -40,887-42,166-11,730-11,730 | -11,699-11,493 | -11,493 | -11,495 | -11,496 | -11,484-13,908-19,527 | -19,526-19,501-20,419 | ||||||||||||
Net unrealized gain and translation adjustments | 24,971 | 26,742 | 29,044 | 24,284 | 20,364 | 17,490 | 21,636 | 18,838 | 21,147 | 20,667 | 19,883 | 19,359 | 22,995 | 24,369 | 22,296 | 25,419 | 29,691 | 39,281 | 45,976 | 13.6% |
Other marketable securities revaluation account | 19,891 | 19,648 | 20,268 | 17,009 | 13,012 | 11,984 | 16,119 | 12,047 | 15,362 | 15,341 | 15,612 | 16,165 | 15,729 | 17,026 | 14,261 | 15,070 | 14,746 | 16,044 | 17,953 | |
Land revaluation account | 3,827 | 3,827 | 3,827 | 3,790 | 3,790 | 3,790 | 3,790 | 3,790 | 3,790 | 3,790 | 3,790 | 3,790 | 3,784 | 3,784 | 3,784 | 3,641 | 3,616 | 3,616 | 3,616 | |
Forex adjustment account | 1,510 | 3,468 | 5,095 | 3,581 | 3,630 | 1,751 | 1,728 | 2,700 | 1,652 | 1,142 | 35 | -1,173 | 2,966 | 3,105 | 3,861 | 5,633 | 10,318 | 18,692 | 23,558 | |
Remeasurements of defined benefit plans | -257 | -201 | -145 | -97 | -69 | -35 | -1 | 299 | 341 | 393 | 444 | 575 | 514 | 451 | 389 | 1,073 | 1,009 | 928 | 847 | |
Stock acquisition right | 323 | 346 | 369 | 392 | 415 | 440 | 466 | 491 | 472 | 213 | 223 | 232 | 241 | 234 | 244 | 254 | 263 | 241 | 250 | 0.1% |
Minority interest | 1,252 | 1,271 | 1,298 | 1,295 | 1,363 | 1,373 | 1,417 | 1,470 | 1,378 | 1,458 | 1,453 | 1,510 | 1,589 | 1,614 | 1,697 | 1,717 | 1,847 | 1,955 | 2,074 | 0.6% |
Total Net assets | 243,045 | 250,561 | 252,609 | 248,629 | 243,303 | 244,820 | 250,248 | 250,746 | 249,709 | 252,906 | 250,741 | 253,809 | 256,489 | 260,536 | 253,913 | 254,885 | 251,713 | 266,277 | 271,829 | 80.7% |
Liabilities and Net assets | 289,899 | 301,367 | 303,827 | 295,786 | 290,121 | 296,731 | 307,986 | 307,401 | 297,085 | 298,939 | 296,548 | 299,861 | 299,904 | 309,583 | 303,995 | 302,858 | 307,764 | 327,897 | 336,880 |
―1―
Consolidated Financial Statement
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | YoY | |
(Unit: ¥mn) | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | |
Sales | 33,507 | 69,400 | 102,587 | 143,408 | 29,233 | 63,401 | 99,078 | 140,992 | 24,882 | 52,926 | 80,822 | 114,510 | 27,761 | 58,551 | 86,663 | 120,193 | 26,393 | 59,619 | 91,881 | 106.0% |
CoGS | 13,600 | 26,130 | 38,175 | 54,727 | 10,901 | 22,892 | 34,554 | 53,388 | 9,672 | 19,577 | 30,148 | 45,337 | 11,162 | 23,120 | 34,884 | 50,126 | 11,647 | 25,156 | 39,100 | |
(as a % of sales) | 40.6% | 37.7% | 37.2% | 38.2% | 37.3% | 36.1% | 34.9% | 37.9% | 38.9% | 37.0% | 37.3% | 39.6% | 40.2% | 39.5% | 40.3% | 41.7% | 44.1% | 42.2% | 42.6% | |
Gross profits | 19,906 | 43,270 | 64,412 | 88,680 | 18,331 | 40,509 | 64,523 | 87,603 | 15,210 | 33,349 | 50,674 | 69,173 | 16,599 | 35,430 | 51,779 | 70,067 | 14,745 | 34,462 | 52,781 | 101.9% |
(as a % of sales) | 59.4% | 62.3% | 62.8% | 61.8% | 62.7% | 63.9% | 65.1% | 62.1% | 61.1% | 63.0% | 62.7% | 60.4% | 59.8% | 60.5% | 59.7% | 58.3% | 55.9% | 57.8% | 57.4% | |
SG&A costs | 15,543 | 32,024 | 48,458 | 66,401 | 15,552 | 30,319 | 46,106 | 64,875 | 14,132 | 27,833 | 42,551 | 58,501 | 14,479 | 29,723 | 44,805 | 60,730 | 14,225 | 29,549 | 44,274 | |
(as a % of sales) | 46.4% | 46.1% | 47.2% | 46.3% | 53.2% | 47.8% | 46.5% | 46.0% | 56.8% | 52.6% | 52.6% | 51.1% | 52.2% | 50.8% | 51.7% | 50.5% | 53.9% | 49.6% | 48.2% | |
Sales promotion costs | 3,019 | 6,439 | 10,155 | 13,283 | 2,987 | 6,131 | 9,655 | 13,873 | 3,032 | 5,882 | 9,583 | 13,466 | 3,547 | 7,129 | 10,789 | 13,925 | 2,481 | 5,396 | 7,911 | |
Advertising costs | 2,857 | 6,229 | 9,399 | 13,089 | 3,309 | 6,551 | 10,154 | 14,758 | 2,661 | 5,527 | 8,288 | 11,259 | 2,670 | 5,710 | 8,465 | 11,481 | 2,538 | 5,573 | 8,733 | |
R&D spending | 3,012 | 6,329 | 9,369 | 13,032 | 2,978 | 5,330 | 7,547 | 10,504 | 2,676 | 5,240 | 7,873 | 10,766 | 2,586 | 5,011 | 7,455 | 10,613 | 2,506 | 4,935 | 7,174 | |
Other SG&A expenses | 6,653 | 13,027 | 19,533 | 26,995 | 6,276 | 12,305 | 18,749 | 25,739 | 5,761 | 11,183 | 16,806 | 23,008 | 5,674 | 11,872 | 18,094 | 24,710 | 6,699 | 13,644 | 20,454 | |
Operating profits | 4,362 | 11,245 | 15,954 | 22,278 | 2,778 | 10,190 | 18,417 | 22,727 | 1,078 | 5,516 | 8,123 | 10,671 | 2,120 | 5,706 | 6,973 | 9,337 | 519 | 4,913 | 8,506 | 122.0% |
(as a % of sales) | 13.0% | 16.2% | 15.6% | 15.5% | 9.5% | 16.1% | 18.6% | 16.1% | 4.3% | 10.4% | 10.1% | 9.3% | 7.6% | 9.7% | 8.0% | 7.8% | 2.0% | 8.2% | 9.3% | |
Nonoperating income | 285 | 906 | 1,485 | 2,582 | 453 | 1,182 | 1,729 | 3,165 | 379 | 1,074 | 1,467 | 2,061 | 924 | 1,356 | 1,927 | 3,453 | 1,929 | 4,074 | 4,687 | |
Interest received | 115 | 278 | 467 | 800 | 256 | 520 | 808 | 1,142 | 235 | 430 | 507 | 563 | 33 | 79 | 110 | 153 | 52 | 202 | 398 | |
Dividends received | 70 | 422 | 535 | 763 | 67 | 436 | 537 | 811 | 69 | 463 | 570 | 843 | 96 | 479 | 595 | 905 | 83 | 501 | 626 | |
Foreign exchange gains | - | - | 74 | - | - | - | - | - | - | - | - | - | 584 | 526 | 891 | 1,276 | 1,657 | 3,146 | 3,210 | |
Equity-method investment profits | - | 19 | 124 | 619 | - | - | 82 | 786 | - | - | - | 133 | - | - | - | 569 | - | - | - | |
Other | 99 | 186 | 284 | 399 | 129 | 225 | 300 | 425 | 75 | 181 | 390 | 520 | 209 | 270 | 329 | 548 | 136 | 224 | 452 | |
Nonoperating expenses | 198 | 139 | 28 | 214 | 368 | 730 | 229 | 264 | 1,040 | 1,071 | 1,662 | 903 | 189 | 226 | 235 | 152 | 150 | 118 | 189 | |
Interest paid | 2 | 5 | 16 | 19 | 12 | 8 | 13 | 19 | 2 | 2 | 5 | 10 | 1 | 6 | 11 | 20 | 0 | 4 | 12 | |
Foreign exchange losses | 149 | 121 | - | 178 | 178 | 595 | 197 | 149 | 737 | 745 | 1,149 | 542 | - | - | - | - | - | - | - | |
Other | 47 | 12 | 11 | 17 | 177 | 126 | 19 | 95 | 299 | 323 | 507 | 351 | 188 | 219 | 224 | 131 | 150 | 113 | 177 | |
Recurring profits | 4,449 | 12,012 | 17,412 | 24,647 | 2,863 | 10,641 | 19,917 | 25,628 | 418 | 5,519 | 7,928 | 11,829 | 2,855 | 6,836 | 8,665 | 12,638 | 2,298 | 8,870 | 13,003 | 150.1% |
(as a % of sales) | 13.3% | 17.3% | 17.0% | 17.2% | 9.8% | 16.8% | 20.1% | 18.2% | 1.7% | 10.4% | 9.8% | 10.3% | 10.3% | 11.7% | 10.0% | 10.5% | 8.7% | 14.9% | 14.2% | |
Extraordinary profits | 0 | 218 | 218 | 1,312 | - | - | 1,610 | 1,685 | 1 | 1 | 356 | 408 | 659 | 659 | 659 | 660 | 141 | 142 | 142 | |
Gain on sales of investment securities | - | 218 | 218 | 1,312 | - | - | - | - | 1 | 1 | 136 | 188 | 652 | 652 | 652 | 653 | - | - | - | |
Public subsidies | - | - | - | - | - | - | - | - | - | - | - | 2 | - | - | - | - | - | - | - | |
Other | 0 | - | 0 | 0 | - | - | 1,610 | 1,685 | - | - | 219 | 218 | 6 | 6 | 6 | 7 | 141 | 142 | 142 | |
Extraordinary losses | 0 | 10 | 9 | 285 | 1 | 4 | 10 | 1,159 | 0 | 5 | 21 | 40 | 29 | 328 | 333 | 342 | 41 | 77 | 116 | |
Losses on fixed asset disposal | 0 | 10 | 9 | 72 | 1 | 4 | 10 | 28 | 0 | 5 | 21 | 40 | 29 | 48 | 53 | 62 | 41 | 77 | 116 | |
Impairment loss | - | - | - | 138 | - | - | - | 953 | - | - | - | - | - | - | - | - | - | - | - | |
Valuation losses on investment securities | - | - | - | - | - | - | - | 176 | - | - | - | - | - | - | - | - | - | - | - | |
Other | - | - | - | 74 | - | - | - | - | - | - | - | - | - | 279 | 279 | 279 | - | - | - | |
Pretax profits | 4,449 | 12,221 | 17,621 | 25,673 | 2,862 | 10,637 | 21,518 | 26,155 | 418 | 5,515 | 8,263 | 12,197 | 3,485 | 7,168 | 8,992 | 12,956 | 2,398 | 8,935 | 13,029 | 144.9% |
Tax, etc. | 996 | 3,063 | 4,292 | 6,468 | 948 | 3,088 | 6,097 | 7,461 | 305 | 1,822 | 2,540 | 2,946 | 1,122 | 2,165 | 2,773 | 3,297 | 766 | 2,430 | 3,507 | |
Net profits | 3,452 | 9,158 | 13,329 | 19,204 | 1,913 | 7,548 | 15,420 | 18,694 | 113 | 3,693 | 5,722 | 9,250 | 2,362 | 5,002 | 6,218 | 9,658 | 1,631 | 6,504 | 9,522 | 153.1% |
(as a % of sales) | 10.3% | 13.2% | 13.0% | 13.4% | 6.5% | 11.9% | 15.6% | 13.3% | 0.5% | 7.0% | 7.1% | 8.1% | 8.5% | 8.5% | 7.2% | 8.0% | 6.2% | 10.9% | 10.4% | |
Capex | 1,829 | 4,066 | 1,412 | 3,743 | 1,897 | 3,647 | 1,796 | 5,314 | 4,380 | |||||||||||
(as a % of sales) | 2.6% | 2.8% | 2.2% | 2.7% | 3.6% | 3.2% | 3.1% | 4.4% | 7.3% | |||||||||||
Depreciation | 2,075 | 4,213 | 2,607 | 4,214 | 1,923 | 4,058 | 1,964 | 4,287 | 2,116 | |||||||||||
(as a % of sales) | 3.0% | 2.9% | 4.1% | 3.0% | 3.6% | 3.5% | 3.4% | 3.6% | 3.5% | |||||||||||
Goodwill amortization | 542 | 1,528 | 10 | 20 | 10 | 20 | 10 | 35 | 23 | |||||||||||
Number of employees | 2,892 | 2,792 | 2,787 | 2,745 | 2,786 | 2,770 | 2,825 | 2,784 | 2,785 | |||||||||||
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | YoY | |
(Unit: ¥mn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |
Sales | 33,507 | 35,893 | 33,186 | 40,820 | 29,233 | 34,168 | 35,676 | 41,913 | 24,882 | 28,043 | 27,896 | 33,687 | 27,761 | 30,789 | 28,112 | 33,530 | 26,393 | 33,226 | 32,261 | 114.8% |
CoGS | 13,600 | 12,529 | 12,044 | 16,552 | 10,901 | 11,990 | 11,662 | 18,834 | 9,672 | 9,904 | 10,570 | 15,189 | 11,162 | 11,958 | 11,763 | 15,241 | 11,647 | 13,509 | 13,943 | |
(as a % of sales) | 40.6% | 34.9% | 36.3% | 40.5% | 37.3% | 35.1% | 32.7% | 44.9% | 38.9% | 35.3% | 37.9% | 45.1% | 40.2% | 38.8% | 41.8% | 45.5% | 44.1% | 40.7% | 43.2% | |
Gross profits | 19,906 | 23,363 | 21,142 | 24,268 | 18,331 | 22,177 | 24,014 | 23,079 | 15,210 | 18,138 | 17,325 | 18,498 | 16,599 | 18,830 | 16,348 | 18,288 | 14,745 | 19,717 | 18,318 | 112.0% |
(as a % of sales) | 59.4% | 65.1% | 63.7% | 59.5% | 62.7% | 64.9% | 67.3% | 55.1% | 61.1% | 64.7% | 62.1% | 54.9% | 59.8% | 61.2% | 58.2% | 54.5% | 55.9% | 59.3% | 56.8% | |
SG&A costs | 15,543 | 16,480 | 16,433 | 17,943 | 15,552 | 14,766 | 15,786 | 18,769 | 14,132 | 13,701 | 14,718 | 15,950 | 14,479 | 15,244 | 15,081 | 15,924 | 14,225 | 15,324 | 14,725 | |
(as a % of sales) | 46.4% | 45.9% | 49.5% | 44.0% | 53.2% | 43.2% | 44.2% | 44.8% | 56.8% | 48.9% | 52.8% | 47.3% | 52.2% | 49.5% | 53.6% | 47.5% | 53.9% | 46.1% | 45.6% | |
Sales promotion costs | 3,019 | 3,419 | 3,715 | 3,128 | 2,987 | 3,144 | 3,523 | 4,218 | 3,032 | 2,850 | 3,700 | 3,883 | 3,547 | 3,581 | 3,660 | 3,136 | 2,481 | 2,915 | 2,515 | |
Advertising costs | 2,857 | 3,371 | 3,170 | 3,690 | 3,309 | 3,241 | 3,602 | 4,604 | 2,661 | 2,865 | 2,761 | 2,970 | 2,670 | 3,039 | 2,754 | 3,016 | 2,538 | 3,034 | 3,160 | |
R&D spending | 3,012 | 3,316 | 3,040 | 3,663 | 2,978 | 2,351 | 2,216 | 2,957 | 2,676 | 2,563 | 2,632 | 2,893 | 2,586 | 2,425 | 2,444 | 3,157 | 2,506 | 2,429 | 2,239 | |
Other SG&A expenses | 6,653 | 6,373 | 6,506 | 7,461 | 6,276 | 6,028 | 6,444 | 6,990 | 5,761 | 5,421 | 5,623 | 6,201 | 5,674 | 6,198 | 6,222 | 6,615 | 6,699 | 6,945 | 6,809 | |
Operating profits | 4,362 | 6,882 | 4,708 | 6,324 | 2,778 | 7,411 | 8,227 | 4,309 | 1,078 | 4,437 | 2,607 | 2,548 | 2,120 | 3,586 | 1,266 | 2,363 | 519 | 4,393 | 3,592 | 283.7% |
(as a % of sales) | 13.0% | 19.2% | 14.2% | 15.5% | 9.5% | 21.7% | 23.1% | 10.3% | 4.3% | 15.8% | 9.3% | 7.6% | 7.6% | 11.6% | 4.5% | 7.0% | 2.0% | 13.2% | 11.1% | |
Nonoperating income | 285 | 621 | 579 | 1,096 | 453 | 782 | 1,056 | 1,483 | 379 | 707 | 444 | 1,408 | 924 | 497 | 648 | 1,600 | 1,929 | 2,185 | 646 | |
Interest received | 115 | 163 | 188 | 332 | 256 | 263 | 287 | 334 | 235 | 194 | 77 | 56 | 33 | 45 | 30 | 43 | 52 | 150 | 196 | |
Dividends received | 70 | 351 | 113 | 227 | 67 | 368 | 101 | 273 | 69 | 393 | 106 | 273 | 96 | 382 | 116 | 309 | 83 | 417 | 124 | |
Foreign exchange gains | - | 27 | 196 | - | - | - | 398 | 47 | - | - | - | 607 | 584 | - | 365 | 384 | 1,657 | 1,489 | 64 | |
Equity-method investment profits | - | 36 | 104 | 495 | - | 54 | 193 | 703 | - | 12 | 51 | 341 | - | 8 | 77 | 644 | - | 39 | 33 | |
Other | 99 | 86 | 98 | 114 | 129 | 96 | 75 | 124 | 75 | 106 | 209 | 130 | 209 | 61 | 58 | 219 | 136 | 88 | 227 | |
Nonoperating expenses | 198 | -14 | 9 | 260 | 368 | 416 | 8 | 82 | 1,040 | 43 | 642 | 56 | 189 | 101 | 86 | -8 | 150 | 6 | 105 | |
Interest paid | 2 | 3 | 10 | 3 | 12 | 5 | 4 | 6 | 2 | 0 | 3 | 5 | 1 | 5 | 4 | 9 | 0 | 4 | 7 | |
Foreign exchange losses | 149 | - | - | 252 | 178 | 417 | - | - | 737 | 8 | 403 | - | - | 57 | - | - | - | - | - | |
Other | 47 | -17 | -0 | 5 | 177 | -6 | 3 | 76 | 299 | 36 | 235 | 51 | 188 | 39 | 81 | -18 | 150 | 2 | 98 | |
Recurring profits | 4,449 | 7,562 | 5,399 | 7,234 | 2,863 | 7,777 | 9,276 | 5,710 | 418 | 5,101 | 2,409 | 3,900 | 2,855 | 3,981 | 1,828 | 3,972 | 2,298 | 6,571 | 4,133 | 226.1% |
(as a % of sales) | 13.3% | 21.1% | 16.3% | 17.7% | 9.8% | 22.8% | 26.0% | 13.6% | 1.7% | 18.2% | 8.6% | 11.6% | 10.3% | 12.9% | 6.5% | 11.8% | 8.7% | 19.8% | 12.8% | |
Extraordinary profits | 0 | 218 | 0 | 1,093 | - | - | 1,610 | 74 | 1 | - | 354 | 52 | 659 | 0 | - | 0 | 141 | 0 | - | |
Gain on sales of investment securities | - | 218 | - | 1,093 | - | - | - | - | 1 | - | 134 | 52 | 652 | - | - | 0 | - | - | - | |
Public subsidies | - | - | - | - | - | - | - | - | - | - | - | 2 | - | - | - | - | - | - | - | |
Other | 0 | -0 | 0 | - | - | - | 1,610 | 74 | - | - | 219 | -1 | 6 | 0 | - | 0 | 141 | 0 | - | |
Extraordinary losses | 0 | 9 | -0 | 276 | 1 | 2 | 5 | 1,148 | 0 | 4 | 16 | 18 | 29 | 298 | 4 | 8 | 41 | 35 | 39 | |
Losses on fixed asset disposal | 0 | 9 | -0 | 63 | 1 | 2 | 5 | 18 | 0 | 4 | 16 | 18 | 29 | 19 | 4 | 8 | 41 | 35 | 39 | |
Impairment loss | - | - | - | 138 | - | - | - | 953 | - | - | - | - | - | - | - | - | - | - | - | |
Valuation losses on investment securities | - | - | - | - | - | - | - | 176 | - | - | - | - | - | - | - | - | - | - | - | |
Other | - | - | - | 74 | - | - | - | - | - | - | - | - | - | 279 | - | - | - | - | - | |
Pretax profits | 4,449 | 7,772 | 5,400 | 8,051 | 2,862 | 7,774 | 10,881 | 4,636 | 418 | 5,096 | 2,747 | 3,934 | 3,485 | 3,682 | 1,823 | 3,964 | 2,398 | 6,536 | 4,094 | 224.5% |
Tax, etc. | 996 | 2,066 | 1,229 | 2,176 | 948 | 2,140 | 3,009 | 1,363 | 305 | 1,516 | 718 | 406 | 1,122 | 1,043 | 607 | 929 | 766 | 1,663 | 1,076 | |
Net profits | 3,452 | 5,705 | 4,171 | 5,875 | 1,913 | 5,634 | 7,872 | 3,273 | 113 | 3,579 | 2,029 | 3,528 | 2,362 | 2,639 | 1,216 | 3,034 | 1,631 | 4,873 | 3,017 | 248.2% |
(as a % of sales) | 10.3% | 15.9% | 12.6% | 14.4% | 6.5% | 16.5% | 22.1% | 7.8% | 0.5% | 12.8% | 7.3% | 10.5% | 8.5% | 8.6% | 4.3% | 9.1% | 6.2% | 14.7% | 9.4% |
―2―
Sales results by region
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | YoY | |
(Unit: ¥mn) | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | |
Rx Business | 19,861 | 42,085 | 63,298 | 85,881 | 17,729 | 37,728 | 61,344 | 81,379 | 15,545 | 32,118 | 48,316 | 66,066 | 16,468 | 33,885 | 51,039 | 68,469 | 15,853 | 33,935 | 52,041 | 102.0% |
Japan | 15,726 | 32,578 | 49,358 | 67,384 | 13,792 | 29,467 | 49,468 | 65,080 | 12,079 | 25,377 | 38,816 | 52,181 | 13,180 | 27,061 | 41,040 | 54,546 | 12,509 | 26,343 | 40,162 | 97.9% |
USA | 3,624 | 8,066 | 11,867 | 15,628 | 3,177 | 6,577 | 9,233 | 12,262 | 2,574 | 5,066 | 7,247 | 10,169 | 2,377 | 4,651 | 6,780 | 9,586 | 2,531 | 5,472 | 8,496 | 125.3% |
Other regions | 511 | 1,440 | 2,072 | 2,869 | 759 | 1,683 | 2,642 | 4,036 | 892 | 1,675 | 2,253 | 3,715 | 909 | 2,172 | 3,218 | 4,336 | 812 | 2,119 | 3,382 | 105.1% |
OTC Business | 12,790 | 25,594 | 36,707 | 54,079 | 10,842 | 24,359 | 35,765 | 56,971 | 8,680 | 19,479 | 30,466 | 45,693 | 10,581 | 23,233 | 33,474 | 48,822 | 9,778 | 24,159 | 37,542 | 112.2% |
Japan | 8,077 | 14,619 | 20,579 | 28,529 | 6,574 | 13,659 | 19,223 | 29,682 | 3,688 | 8,856 | 13,916 | 20,239 | 4,891 | 10,370 | 14,042 | 21,280 | 3,049 | 8,073 | 11,745 | 83.6% |
USA | 2,181 | 5,836 | 8,231 | 11,137 | 2,897 | 5,972 | 8,644 | 12,103 | 3,254 | 5,966 | 8,986 | 12,087 | 3,573 | 7,258 | 10,079 | 12,519 | 3,529 | 7,723 | 12,024 | 119.3% |
Other regions | 2,531 | 5,138 | 7,896 | 14,413 | 1,371 | 4,727 | 7,897 | 15,186 | 1,737 | 4,656 | 7,562 | 13,367 | 2,116 | 5,603 | 9,352 | 15,021 | 3,198 | 8,362 | 13,772 | 147.3% |
Others | 856 | 1,720 | 2,582 | 3,447 | 661 | 1,313 | 1,969 | 2,640 | 656 | 1,328 | 2,039 | 2,749 | 712 | 1,432 | 2,149 | 2,901 | 761 | 1,524 | 2,297 | 106.9% |
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | YoY | |
(Unit: ¥mn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |
Rx Business | 19,861 | 22,223 | 21,213 | 22,582 | 17,729 | 19,999 | 23,615 | 20,035 | 15,545 | 16,572 | 16,198 | 17,749 | 16,468 | 17,417 | 17,153 | 17,430 | 15,853 | 18,082 | 18,106 | 105.6% |
Japan | 15,726 | 16,852 | 16,779 | 18,025 | 13,792 | 15,675 | 20,000 | 15,612 | 12,079 | 13,297 | 13,439 | 13,365 | 13,180 | 13,880 | 13,978 | 13,506 | 12,509 | 13,833 | 13,818 | 98.9% |
USA | 3,624 | 4,442 | 3,800 | 3,761 | 3,177 | 3,400 | 2,655 | 3,029 | 2,574 | 2,491 | 2,181 | 2,922 | 2,377 | 2,274 | 2,128 | 2,806 | 2,531 | 2,941 | 3,024 | 142.1% |
Other regions | 511 | 929 | 632 | 796 | 759 | 924 | 958 | 1,394 | 892 | 782 | 578 | 1,462 | 909 | 1,262 | 1,046 | 1,117 | 812 | 1,306 | 1,263 | 120.7% |
OTC Business | 12,790 | 12,804 | 11,112 | 17,372 | 10,842 | 13,516 | 11,405 | 21,206 | 8,680 | 10,798 | 10,986 | 15,227 | 10,581 | 12,651 | 10,241 | 15,347 | 9,778 | 14,381 | 13,382 | 130.7% |
Japan | 8,077 | 6,542 | 5,959 | 7,949 | 6,574 | 7,085 | 5,563 | 10,458 | 3,688 | 5,168 | 5,060 | 6,322 | 4,891 | 5,478 | 3,672 | 7,237 | 3,049 | 5,023 | 3,672 | 100.0% |
USA | 2,181 | 3,655 | 2,394 | 2,906 | 2,897 | 3,074 | 2,672 | 3,458 | 3,254 | 2,711 | 3,020 | 3,100 | 3,573 | 3,685 | 2,820 | 2,440 | 3,529 | 4,193 | 4,300 | 152.5% |
Other regions | 2,531 | 2,606 | 2,758 | 6,516 | 1,371 | 3,356 | 3,169 | 7,289 | 1,737 | 2,918 | 2,906 | 5,805 | 2,116 | 3,487 | 3,748 | 5,669 | 3,198 | 5,163 | 5,409 | 144.3% |
Others | 856 | 864 | 861 | 865 | 661 | 652 | 655 | 671 | 656 | 672 | 711 | 710 | 712 | 720 | 717 | 752 | 761 | 763 | 772 | 107.7% |
―3―
Sales Results of Major Products
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | YoY | |
(Unit: ¥mn) | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | Q1-Q4 | Q1 | Q1-Q2 | Q1-Q3 | ||
Mohrus® Tape products | 9,973 | 20,805 | 31,586 | 42,115 | 8,950 | 19,454 | 28,650 | 39,091 | 7,545 | 16,313 | 24,866 | 33,450 | 7,689 | 15,745 | 24,097 | 32,162 | 6,872 | 14,121 | 21,480 | 89.1% |
Zicthoru® Tapes | - | - | - | - | - | - | - | - | - | - | - | - | 34 | 82 | 155 | 238 | 93 | 913 | 1,365 | 879.0% |
Haruropi® Tape | - | - | - | - | - | - | - | 674 | 441 | 630 | 842 | 1,185 | 798 | 1,780 | 2,512 | 3,614 | 604 | 1,537 | 2,370 | 94.4% |
Mohrus® Pap products | 1,745 | 3,727 | 5,674 | 7,447 | 1,509 | 3,315 | 4,849 | 6,407 | 1,129 | 2,543 | 3,901 | 5,125 | 1,185 | 2,445 | 3,736 | 4,846 | 981 | 2,021 | 3,066 | 82.1% |
Fentos® Tapes | 1,333 | 2,652 | 3,897 | 4,852 | 1,090 | 2,176 | 3,313 | 4,155 | 1,031 | 1,713 | 2,676 | 3,569 | 936 | 1,912 | 2,745 | 3,507 | 1,013 | 1,999 | 2,886 | 105.1% |
Allesaga® Tapes | 99 | 102 | 109 | 230 | 75 | 98 | 136 | 356 | 55 | 86 | 148 | 291 | 149 | 203 | 284 | 422 | 134 | 192 | 269 | 94.6% |
0 | - | - | - | - | - | |||||||||||||||
CombiPatch® products | 1,082 | 2,172 | 3,289 | 4,428 | 1,003 | 1,924 | 3,117 | 4,335 | 1,159 | 2,367 | 3,440 | 4,882 | 1,103 | 2,504 | 3,728 | 5,163 | 1,415 | 2,971 | 4,793 | 128.5% |
Vivelle-Dot® products | 883 | 2,343 | 3,298 | 4,190 | 1,324 | 3,051 | 3,772 | 4,917 | 891 | 1,708 | 2,451 | 3,778 | 1,067 | 2,255 | 3,320 | 4,212 | 1,138 | 2,411 | 3,990 | 120.2% |
Minivelle® products | 1,433 | 3,441 | 4,851 | 6,098 | 818 | 1,656 | 2,494 | 3,249 | 617 | 1,167 | 1,779 | 2,510 | 517 | 993 | 1,436 | 1,975 | 447 | 977 | 1,593 | 110.9% |
Daytrana® | 615 | 1,108 | 1,830 | 2,520 | 661 | 1,156 | 1,793 | 2,490 | 631 | 1,285 | 1,630 | 2,183 | 691 | 1,076 | 1,486 | 2,081 | 330 | 803 | 1,052 | 70.8% |
Secuado® | - | - | - | - | - | - | - | - | 61 | 75 | 88 | 148 | 70 | 148 | 252 | 383 | 148 | 282 | 453 | 180.0% |
0 | - | - | - | - | - | - | - | |||||||||||||
Salonpas® products | 7,024 | 15,606 | 22,737 | 33,062 | 6,636 | 15,382 | 22,828 | 34,456 | 5,724 | 12,639 | 20,528 | 29,803 | 6,932 | 15,233 | 22,505 | 31,095 | 7,108 | 17,238 | 27,360 | 121.6% |
Feitas® products | 1,427 | 2,925 | 4,526 | 5,811 | 1,384 | 3,169 | 4,495 | 5,914 | 903 | 2,173 | 3,374 | 4,582 | 1,065 | 2,441 | 3,293 | 4,603 | 598 | 1,776 | 2,735 | 83.0% |
Salonsip® products | 822 | 1,814 | 2,568 | 3,414 | 575 | 1,636 | 2,624 | 3,988 | 422 | 1,370 | 2,172 | 3,224 | 600 | 1,718 | 2,426 | 3,204 | 621 | 1,616 | 2,415 | 99.5% |
Allegra® FX | 1,393 | 1,420 | 1,681 | 4,509 | 413 | 644 | 1,059 | 5,303 | 95 | 69 | 103 | 2,255 | 362 | 527 | 827 | 4,014 | 125 | 228 | 563 | 68.1% |
Air® Salonpas® products | 421 | 1,017 | 1,411 | 1,789 | 370 | 907 | 1,276 | 1,701 | 268 | 796 | 1,144 | 1,493 | 338 | 746 | 1,019 | 1,297 | 330 | 822 | 1,118 | 109.8% |
Butenalock® products | 948 | 1,228 | 1,401 | 1,672 | 818 | 1,124 | 1,262 | 1,683 | 476 | 884 | 1,048 | 1,311 | 629 | 1,025 | 1,146 | 1,453 | 425 | 674 | 487 | 42.5% |
0 | ||||||||||||||||||||
2018.05 | 2018.08 | 2018.11 | 2019.02 | 2019.05 | 2019.08 | 2019.11 | 2020.02 | 2020.05 | 2020.08 | 2020.11 | 2021.02 | 2021.05 | 2021.08 | 2021.11 | 2022.02 | 2022.05 | 2022.08 | 2022.11 | YoY | |
(Unit: ¥mn) | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |
Mohrus® Tape products | 9,973 | 10,832 | 10,780 | 10,529 | 8,950 | 10,504 | 9,195 | 10,441 | 7,545 | 8,767 | 8,552 | 8,584 | 7,689 | 8,055 | 8,352 | 8,065 | 6,872 | 7,249 | 7,358 | 88.1% |
Zicthoru® Tapes | - | - | - | - | - | - | - | - | - | - | - | - | 34 | 48 | 72 | 82 | 93 | 820 | 451 | 619.2% |
Haruropi® Tape | - | - | - | - | - | - | - | 674 | 441 | 189 | 211 | 343 | 798 | 982 | 731 | 1,102 | 604 | 933 | 833 | 113.9% |
Mohrus® Pap products | 1,745 | 1,982 | 1,946 | 1,773 | 1,509 | 1,806 | 1,533 | 1,558 | 1,129 | 1,414 | 1,357 | 1,223 | 1,185 | 1,259 | 1,291 | 1,109 | 981 | 1,039 | 1,045 | 80.9% |
Fentos® Tapes | 1,333 | 1,318 | 1,244 | 954 | 1,090 | 1,086 | 1,136 | 841 | 1,031 | 682 | 962 | 893 | 936 | 975 | 833 | 761 | 1,013 | 986 | 887 | 106.5% |
Allesaga® Tapes | 99 | 2 | 6 | 121 | 75 | 22 | 37 | 220 | 55 | 30 | 61 | 142 | 149 | 54 | 80 | 137 | 134 | 57 | 77 | 95.1% |
CombiPatch® products | 1,082 | 1,090 | 1,116 | 1,138 | 1,003 | 921 | 1,193 | 1,218 | 1,159 | 1,207 | 1,073 | 1,442 | 1,103 | 1,401 | 1,224 | 1,434 | 1,415 | 1,556 | 1,821 | 148.8% |
Vivelle-Dot® products | 883 | 1,459 | 954 | 892 | 1,324 | 1,727 | 720 | 1,145 | 891 | 816 | 742 | 1,327 | 1,067 | 1,187 | 1,064 | 892 | 1,138 | 1,272 | 1,579 | 148.4% |
Minivelle® products | 1,433 | 2,007 | 1,410 | 1,246 | 818 | 837 | 838 | 755 | 617 | 550 | 611 | 731 | 517 | 476 | 442 | 538 | 447 | 529 | 615 | 139.1% |
Daytrana® | 615 | 493 | 722 | 689 | 661 | 495 | 636 | 696 | 631 | 653 | 345 | 552 | 691 | 384 | 410 | 594 | 330 | 473 | 248 | 60.6% |
Secuado® | - | - | - | - | - | - | - | - | 61 | 13 | 13 | 59 | 70 | 78 | 104 | 131 | 148 | 134 | 171 | 164.5% |
Salonpas® products | 7,024 | 8,582 | 7,130 | 10,324 | 6,636 | 8,745 | 7,446 | 11,628 | 5,724 | 6,915 | 7,889 | 9,274 | 6,932 | 8,301 | 7,271 | 8,589 | 7,108 | 10,130 | 10,122 | 139.2% |
Feitas® products | 1,427 | 1,498 | 1,600 | 1,284 | 1,384 | 1,785 | 1,326 | 1,419 | 903 | 1,269 | 1,201 | 1,208 | 1,065 | 1,376 | 852 | 1,309 | 598 | 1,177 | 959 | 112.5% |
Salonsip® products | 822 | 992 | 753 | 845 | 575 | 1,060 | 987 | 1,364 | 422 | 948 | 801 | 1,051 | 600 | 1,117 | 708 | 777 | 621 | 995 | 798 | 112.8% |
Allegra® FX | 1,393 | 27 | 261 | 2,827 | 413 | 230 | 415 | 4,244 | 95 | -26 | 34 | 2,151 | 362 | 165 | 300 | 3,186 | 125 | 102 | 335 | 111.5% |
Air® Salonpas® products | 421 | 595 | 393 | 378 | 370 | 536 | 369 | 425 | 268 | 528 | 347 | 348 | 338 | 407 | 273 | 278 | 330 | 492 | 295 | 108.3% |
Butenalock® products | 948 | 279 | 173 | 271 | 818 | 306 | 137 | 420 | 476 | 407 | 163 | 263 | 629 | 396 | 121 | 306 | 425 | 248 | -186 | -154.1% |
―4―
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 12 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2023 06:19:08 UTC.